All Posts
Clinical Trial Update | Nivolumab plus Relatlimab for advanced melanoma fail to reach OS threshold despite PFS improvement
25 Apr, 2023 | 14:25h | UTCOverall Survival and Response with Nivolumab and Relatlimab in Advanced Melanoma – NEJM Evidence
Original Study: Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma – New England Journal of Medicine
Commentary on Twitter
Original Article: “Overall Survival and Response with Nivolumab and Relatlimab in Advanced Melanoma,” by Georgina V. Long, MD, PhD, et al. https://t.co/g5N1AYQV1I#OncoAlert #Melanoma
— NEJM Evidence (@NEJMEvidence) April 19, 2023
Cohort Study | Osmotic demyelination syndrome in patients hospitalized with hyponatremia
25 Apr, 2023 | 14:26h | UTCOsmotic Demyelination Syndrome in Patients Hospitalized with Hyponatremia – NEJM Evidence
RCT | Intraperitoneal carboplatin achieves modest PFS gains in advanced ovarian cancer
25 Apr, 2023 | 14:24h | UTCIntraperitoneal Carboplatin for Ovarian Cancer — A Phase 2/3 Trial – NEJM Evidence
Commentary on Twitter
“In the first-line treatment of advanced epithelial ovarian cancer, intraperitoneal carboplatin resulted in a modest prolongation of PFS [progression-free survival] when given with dose-dense weekly paclitaxel regardless of residual tumor size….”#MedTwitter #ClinicalTrials
— NEJM Evidence (@NEJMEvidence) April 23, 2023
SR | Angiogenesis inhibitors for the treatment of epithelial ovarian cancer
25 Apr, 2023 | 14:22h | UTCAngiogenesis inhibitors for the treatment of epithelial ovarian cancer – Cochrane Library
Brief Review | Diagnosis and management of adrenal insufficiency
25 Apr, 2023 | 14:18h | UTCDiagnosis and management of adrenal insufficiency – Clinical Medicine Journal
Brief Review | Diagnosis and management of neuroendocrine tumors
25 Apr, 2023 | 14:16h | UTCDiagnosis and management of neuroendocrine tumours – Clinical Medicine Journal
Brief Review | Management of pituitary incidentalomas
25 Apr, 2023 | 14:14h | UTCManagement of pituitary incidentalomas – Clinical Medicine Journal
Brief Review | Investigation and assessment of adrenal incidentalomas
25 Apr, 2023 | 14:13h | UTCInvestigation and assessment of adrenal incidentalomas – Clinical Medicine Journal
Brief Review | Thyroid disease in pregnancy
25 Apr, 2023 | 14:15h | UTCThyroid disease in pregnancy – Clinical Medicine Journal
Consensus Paper | Management of pathological thoracolumbar vertebral fractures in patients with multiple myeloma
25 Apr, 2023 | 14:11h | UTC
Geriatric odontoid fractures: treatment algorithms based on expert consensus and a systematic review
25 Apr, 2023 | 14:08h | UTC
USPSTF Statement | There is insufficient evidence to guide skin cancer screening recommendations
24 Apr, 2023 | 14:07h | UTCScreening for Skin Cancer: US Preventive Services Task Force Recommendation Statement – JAMA
Evidence Report: Skin Cancer Screening: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force – JAMA
Editorials:
Patient Page: Screening and Prevention of Skin Cancer – JAMA
Author Interview: USPSTF Recommendation: Screening for Skin Cancer – JAMA
Commentary on Twitter
2023 Recommendation Statement from the USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of visual skin examination by a clinician to screen for #skincancer in adolescents and adults (I statement). https://t.co/WB6VN2r1Nv
— JAMA (@JAMA_current) April 18, 2023
WHO releases first-ever Standard on universal access to rapid TB diagnostics
24 Apr, 2023 | 14:04h | UTCNews Release: WHO releases first-ever Standard on universal access to rapid TB diagnostics – World Health Organization
WHO Standard: Universal access to rapid tuberculosis diagnostics – World Health Organization
RCT | Oral fluvoxamine plus inhaled budesonide reduced hospitalizations in high-risk patients with early-onset COVID-19
24 Apr, 2023 | 13:51h | UTC
Commentary on Twitter
Treatment w/ oral fluvoxamine + inhaled budesonide among high-risk outpatients w/ early #COVID19 reduced incidence of severe disease requiring advanced care. The combined effect seems to offer benefits over individual use of each drug: https://t.co/wM2da5a5MD pic.twitter.com/Sl1qFzTOjD
— Annals of Int Med (@AnnalsofIM) April 19, 2023
RCT | Bariatric–metabolic surgery is more effective than lifestyle intervention plus best medical care in non-alcoholic steatohepatitis
24 Apr, 2023 | 14:03h | UTCNews Release: Surgery most effective treatment of metabolic liver disease – King’s College London
Commentary on Twitter
New @TheLancet – Verrastro et al – Bariatric–metabolic surgery versus lifestyle intervention plus best medical care in non-alcoholic steatohepatitis (BRAVES): a multicentre, open-label, randomised trialhttps://t.co/pCWahvbReQ#NASH #NAFLD #fattyliver #livertwitter pic.twitter.com/xNMsAskJF9
— The Lancet Gastroenterology & Hepatology (@LancetGastroHep) April 21, 2023
RCT | Higher dose corticosteroids increase mortality in hypoxic COVID-19 patients on simple oxygen
24 Apr, 2023 | 13:55h | UTCEditorial: Higher-dose dexamethasone for patients with COVID-19 and hypoxaemia? – The Lancet
Commentary: Higher-dose corticosteroids tied to 60% more deaths in low-oxygen COVID patients – CIDRAP
Commentary on Twitter (thread – click for more)
Low-dose corticosteroids have been shown to reduce mortality for patients with COVID-19 requiring oxygen or ventilatory support.
A new study evaluated the use of a higher dose of corticosteroids in this patient group. https://t.co/uJGSYSBQAO
— The Lancet (@TheLancet) April 13, 2023
RCT | No difference in atrial fibrillation recurrence with early vs. delayed AF ablation at 12 months
24 Apr, 2023 | 13:49h | UTCImpact of Early Versus Delayed Atrial Fibrillation Catheter Ablation on Atrial Arrhythmia Recurrences – European Heart Journal (link to abstract – $ for full-text. Free PDF may be available here)
Commentary on Twitter
Early versus delayed ablation strategy in atrial fibrillation: read the impact on arrhythmia free survival on #EHJ!#EHRA2023 #EHJ #cardiotwitter #ablation #AF @ESC_Journals @escardio https://t.co/RW9RPry5Vi pic.twitter.com/2iHW49T3Wp
— EHJ Editor-in-Chief (@ehj_ed) April 18, 2023
Evidence Analysis | Blood pressure targets – how low can you get?
24 Apr, 2023 | 13:47h | UTCBlood pressure targets – how low can you get? – Evidently Cochrane
Original Article: SR | Blood pressure targets for the treatment of people with hypertension and cardiovascular disease.
Commentary on Twitter
Blood pressure targets – how low can you get? https://t.co/ERLm6Mihl8 In this @CochraneUK blog, GP @rtwalton123 looks at the latest guidance & @CochraneLibrary evidence on what #BloodPressure targets to aim for, balancing the benefits of treatment against risk of side effects. pic.twitter.com/8EQH0JLzzc
— The Cochrane Library (@CochraneLibrary) April 19, 2023
Prehospital guidelines for the management of traumatic brain injury
24 Apr, 2023 | 13:45h | UTC
Guideline Update | Diagnosis and management of hypertension in pregnancy
24 Apr, 2023 | 13:43h | UTC
Immediate hypersensitivity reactions to antineoplastic agents – A practical guide for the oncologist
24 Apr, 2023 | 13:40h | UTCImmediate hypersensitivity reactions to antineoplastic agents – A practical guide for the oncologist- Cancer Treatment Reviews (free for a limited period)
See Tweet from one of the authors with infographic and link to free full text here
RCT | Panitumumab vs. Bevacizumab added to 1st-line chemo in RAS wild-type left-sided metastatic colorectal cancer
24 Apr, 2023 | 13:41h | UTCPanitumumab vs Bevacizumab Added to Standard First-line Chemotherapy and Overall Survival Among Patients With RAS Wild-type, Left-Sided Metastatic Colorectal Cancer: A Randomized Clinical Trial – JAMA (free for a limited period)
Editorial: Anti-EGFR Therapy for Left-Sided RAS Wild-type Colorectal Cancer—PARADIGM Shift – JAMA Oncology (free for a limited period)
Commentary on Twitter
Among patients with RAS wild-type metastatic colorectal cancer, adding panitumumab, vs bevacizumab, to standard first-line chemotherapy significantly improved overall survival in patients with left-sided tumors and in the overall population. https://t.co/Hjh9f3fN1z #AACR23 pic.twitter.com/uZxQUkfNbB
— JAMA (@JAMA_current) April 18, 2023
RCT | Stereotactic radiosurgery vs. conventional radiotherapy for localized vertebral metastases of the spine
24 Apr, 2023 | 13:37h | UTCStereotactic Radiosurgery vs Conventional Radiotherapy for Localized Vertebral Metastases of the Spine: Phase 3 Results of NRG Oncology/RTOG 0631 Randomized Clinical Trial – JAMA Oncology (link to abstract – $ for full-text)
Audio interview: Radiosurgery of Spine Metastasis—NRG/RTOG 0631 RCT Final Results – JAMA
Commentary on Twitter
Phase 3 rand trial of spinal radiosurgery vs. conventional external beam radiation therapy for pts w/spinal metastases showed radiosurgery did not significantly improve pain response at 3mo but showed feasibility that makes it widely used today. https://t.co/LvZY1nbUpS #RadOnc
— JAMA Oncology (@JAMAOnc) April 20, 2023
Cold static preservation at 10°C shows promising results for safely extending lung transplantation timeframes
24 Apr, 2023 | 13:38h | UTCExtension of Cold Static Donor Lung Preservation at 10°C – NEJM Evidence
Commentary on Twitter
Donor lungs for transplantation are stored on ice and transplanted as rapidly as possible. In an advance that may ease transplant logistics, Ali et al. now report that prolonged storage of donor lungs at 10°C may lead to equivalent outcomes.
Read the Original Article:
— NEJM Evidence (@NEJMEvidence) April 22, 2023
Cohort Study | Prehospital end-tidal CO2 levels and mortality in suspected severe traumatic brain injury patients
24 Apr, 2023 | 13:35h | UTCEditorial: Prehospital ventilation targets in severe traumatic brain injury – Intensive Care Medicine
Commentary on Twitter
Prehospital etCO2 in severe #TBI, BRAIN-PROTECT study
🚁 L-shaped association with mortality
🧠 35-45 mmHg seems reasonable target: lower ETCO2? sharp mortality ⬆️
🖇️ https://t.co/DC0DoHa00NWith editorial on MV targets & reliability of available data
🖇️ https://t.co/jVZ4zZVHxv pic.twitter.com/74vKxjyGpA— Intensive Care Medicine (@yourICM) April 20, 2023